Acesion Pharma initiated a Phase 2 trial of AP31969 for atrial fibrillation.
Acesion Pharma ApS is a Danish biotech company pioneering the development of safe and efficacious antiarrhythmic drugs for the treatment of atrial fibrillation, the most common type of cardiac arrhythmia
Acesion Pharma ApS is a Danish biotech company pioneering the development of safe and efficacious antiarrhythmic drugs for the treatment of atrial fibrillation, the most common type of cardiac arrhythmia. The company is focused on developing SK ion channel inhibitors for severe heart diseases.